1. South Korea Stocks

  2. •

    Electronic technology

  3. •

    Electronic production equipment
Keeps Biopharma Inc.

Keeps Biopharma Inc.

KKRX:256940
5,520.00
KRW
-90.00
(-1.60%)
-648.41EPS
119.06BMarket Cap
Nov 12Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,425.3
2,733.03
2,291.06
3,171.35
1,105.2
1,037.14
246.16
780
4,922.93
6,760.49
8,676.71
10,984.09
Basic EPS, GAAP
-239
398
209
531.33
-26.98
-164
-885
-607
210
59
-499
-614.87
Free Cash Flow per Basic Share
-350.51
70.97
536.02
-258.64
-59.15
-233.76
-491.28
-53.15
-60.27
-100.24
-2,539.96
-2,265.6
Dividend per Share
- -
- -
- -
- -
33.32
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-554.24
712.18
2,009.97
2,408.12
2,356.54
3,269.86
3,292.31
2,830.71
3,052.82
2,673.99
3,088.47
3,115.76
Tangible Book Value per Share
-644.94
639.06
1,945.45
2,366.93
2,323.38
3,206.3
3,240.22
2,779.59
1,422.53
499.75
527.42
555.83
Basic Weighted Avg Shares
6
6
10
13
13
15
17
19
19
19
20
20
Sales/Revenue/Turnover
8,556
17,547
24,043
40,628
14,191
15,217
4,261
14,617
92,133
127,583
170,147
220,477
Operating Margin (%)
-10.81
15.52
17.74
20.17
-6.86
-2.54
-288.86
-58.94
3.2
4.87
0.93
-0.27
Depreciation Expense
862
1,121
556
502
711
604
812
993
1,442
2,582
4,488
- -
Net Income, GAAP
-1,435
2,555
2,193
6,807
-346
-2,406
-15,317
-11,375
3,930
1,113
-9,785
-12,342
Effective Tax Rate (%)
- -
15.32
22.82
17.6
- -
- -
- -
- -
35.53
52.17
- -
- -
Profit Margin (%)
-16.77
14.56
9.12
16.75
-2.44
-15.81
-359.52
-77.82
4.27
0.87
-5.75
-5.6
Working Capital
-273
2,747
19,620
18,721
18,399
28,171
33,145
11,251
-9,114
-15,079
21,448
6,473
LT Debt
4,592
2,467
920
460
75
682
572
386
92
13,490
47,500
37,014
Total Equity
-4,864
6,250
25,748
30,913
30,298
50,932
60,887
52,268
58,579
63,415
81,503
79,647
Return on Invested Capital (%)
- -
19.42
13.83
22.56
- -
- -
- -
- -
2.12
2.63
- -
- -
Return on Capital (%)
- -
27.6
9.97
23.11
- -
- -
- -
- -
6.07
2.12
- -
- -
Return on Common Equity (%)
- -
- -
13.71
24.03
-1.13
-5.98
-27.55
-19.94
7.13
2.07
-17.45
-18.01

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
45,093
44,520
58,246
LT Borrowings
47,347
50,056
36,855
LT Finance Leases
154
203
159
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
208,813
153,196
119,063

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
110,856
116,619
107,115
Cash, Cash Equivalents & STI
26,571
31,060
28,987
Accounts Receivable, Net
20,979
31,296
32,892
Inventories
31,524
29,419
30,560
Total Current Liabilities
89,407
92,434
100,642
Payables & Accruals
- -
- -
- -
ST Debt
45,093
44,520
58,246
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.39%
10.85%
28.52%
Free Cash Flow
380.19%
534.71%
2,532.96%
Net Income, GAAP
-26.67%
-134.84%
-978.82%
Sales/Revenue/Turnover
92.65%
154.64%
33.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
31,708
31,508
31,527
32,840
127,583
2025
40,646
43,343
40,926
45,232
170,147
2026
59,435
74,884
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
356
-259
-89
51.34
59
2025
-92
64
-22.46
-438
-499
2026
282.26
-437
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ha-Young Kim
Sector
Electronic technology
Industry
Electronic production equipment
Address
Seoul South Korea
IPO Date
Sep 6, 2017
Website
kpscorp.co.kr
Similar Companies
Bloom Energy Corporation (NYSE:BE)
AXT Inc (NASDAQ:AXTI)
Vertiv Holdings, LLC (NYSE:VRT)
Aehr Test Systems (NASDAQ:AEHR)
Teradyne, Inc. (NASDAQ:TER)
Dixon Technologies (India) Ltd. (NSE:DIXON)
Business
Keeps Biopharma Inc. is a South Korea-based biopharmaceutical and precision manufacturing company engaged in the research, development, manufacturing, and commercial distribution of prescription pharmaceuticals, targeted oncology therapeutics, novel drug delivery technologies, and industrial precision systems. The company operates across pharmaceutical, biotechnology, and precision engineering segments, offering a diverse portfolio of products and clinical programs, including: finished dosage prescription pharmaceuticals and active pharmaceutical ingredients; hospital-administered medications; targeted oncology therapeutics, including Nerlynx (neratinib) for HER2-positive breast cancer; preclinical oncology pipeline assets, including AGK-102 targeting cancer stem cell biomarkers; proprietary oral drug delivery platforms utilizing Oraloid technology designed to formulate oral peptide therapeutics, including oral insulin and oral GLP-1 receptor agonists for metabolic and weight-loss indications; digital therapeutic solutions; and precision manufacturing equipment, comprising fine metal mask tensioners, OLED mask assembly systems, camera module assembly equipment, and optical inspection machinery. Founded in 2000 and headquartered in Seoul, South Korea, with manufacturing facilities in Seocheon-gun, Chungcheongnam-do, the company serves healthcare institutions, hospitals, pharmacies, and technology manufacturers across South Korea and international markets, including the United States. Its organizational network includes key operating subsidiaries such as Bixink Therapeutics, Algok Bio, Keeps Biomed, Korea Global Pharm, and Elpis Pharm. In recent developments, the company executed a comprehensive strategic reorganization to transition its core business from display equipment manufacturing to biopharmaceuticals, officially changing its corporate name from KPS Corp to Keeps Biopharma Inc. in April 2025 and reclassifying its primary industry listing to pharmaceutical manufacturing. To drive this expansion, the company completed several strategic transactions, including the acquisition of pharmaceutical manufacturer Korea Global Pharm in October 2024, the acquisition of oral peptide delivery developer Keeps Biomed in February 2025, and the acquisition of hospital distribution specialist Elpis Pharm in 2026, alongside the divestment of non-core legacy assets to position biopharmaceuticals and pharmaceuticals as its primary commercial revenue driver.